Bio-Thera Launches Adalimumab In China
Qletli Biosimilar Is First Chinese Humira Rival
Bio-Thera Solutions has launched its first product in China, with its Qletli adalimumab biosimilar representing the first Humira rival to be approved under the country’s biosimilars pathway and just the second biosimilar approved overall.
You may also be interested in...
Bio-Thera has joined the ranks of biosimilars developers that have rivals to Stelara in Phase III trials, after kicking off a study for its BAT2206 proposed version of ustekinumab.
Shanghai Henlius Biotech has announced that China’s NMPA has accepted the firm’s filing for its HLX14 denosumab biosimilar. Meanwhile, the company has also announced dosing the first patient in a Phase II clinical trial of its novel HLX10 anti-PD-1 monoclonal antibody.
Bio-Thera, which has just started selling China’s first adalimumab biosimilar rival to AbbVie’s top-selling arthritis treatment Humira, has raised $241m in an IPO on the Shanghai Stock Exchange.